摘要
目的:在老年人群中,小细胞肺癌的治疗难度大,缺乏有临床指导意义的研究数据,本文旨在通过对老年广泛期小细胞肺癌患者预后因素的分析寻找适合老年患者的化疗策略。方法:回顾性分析106例老年广泛期小细胞肺癌患者资料,应用SPSS13.0统计软件对数据进行单因素及COX回归多因素分析,探讨年龄、PS评分、化疗周期、化疗方案、血液学毒性等因素对生存的影响。结果:①单因素分析显示PS评分、化疗与否、化疗周期数、血液学毒性等因素对预后有影响,单药化疗与联合用药预后无明显差别。②COX回归多因素分析显示PS评分(P<0.001)、化疗周期数(P=0.002)是影响预后的因素。③单药化疗的血液学毒性明显低于联合用药,化疗周期数更多。结论:老年广泛期小细胞肺癌患者可从化疗中受益,四周期以上的化疗可明显延长生存时间,对于PS评分较差的患者,单药化疗可能是一个好的选择。
Objective： In the elderly population, treatment of SCLC is more challenging, However, limited prospective data are available to guide treatment decisions in that special population. The purpose of this study is to analyze the prognostic factors of elderly patients received chemotherapy. Methods： A retrospective study had enrolled 106 cases of lung cancer aged over 70 and SPSS 13.0 software was used in univariate analysis and COX regression analysis to analyze factors affecting prognosis, such as age, ECOG PS, chemotherapy and chemotherapy regimen, hematological toxicity and so on. Results： In univariate analysis, ECOG PS, chemotherapy, chemotherapy cycles and hematological toxicity showed affecting prognosis significantly. In COX regression analysis, it showed that ECOG PS （P〈0.001）, chemotherapy cycles （P=0.002） were independent prognostic factors. Conclusion： Elderly lung cancer patients could be benefit from chemotherapy, their survival time may be prolonged when they had received chemotherapy at least 4 cycles. Single-agent chemotherapy would be a good choice for elderly patients with poor performance status.
出处
《现代生物医学进展》
CAS
2012年第33期6506-6508,6600,共4页
Progress in Modern Biomedicine
基金
黑龙江省自然科学基金(B2010565)
关键词
小细胞肺癌
老年
化疗
SCLC
Elderly age
Chemotherapy
